US FDA blazes the transparency trail
This article was originally published in SRA
There has been no shortage of moves to increase transparency at regulatory agencies in the past year or so. The European Medicines Agency has brought in new policies on access to documents and clinical trial data, while side effect data are to be made more easily available. The French regulator, meanwhile, has promised zero tolerance on conflicts of interest among its committee members and more transparency on publishing minutes of its committee meetings.
You may also be interested in...
Coronavirus Notebook: Italy Makes First Use Of EU’s Vaccine Export Control System, More Regulators Issue Guidance On Variants
Ukraine has established a system for issuing emergency use authorizations for COVID-19 vaccines that recognizes authorizations granted by other world regulators.
The Russian backers of the vaccine’s development say that if it receives a marketing authorization in the EU, distribution could begin in June this year.
Coronavirus Notebook: EU Moots Emergency Use Authorization Scheme For Vaccines, Janssen Product Up For 11 March Approval
Celltrion’s regdanvimab is undergoing an emergency use procedure in Europe, the European Medicines Agency and the health authorities in Canada have jointly published clinical data on the Moderna vaccine, and Canada has approved two versions of the AstraZeneca/Oxford University jab.